|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Esophagitis, erosive |
|
Gastroesophageal Reflux Disease |
|
Mastocytosis, systemic |
|
Ulcer, duodenal |
|
Ulcer, gastric |
|
Zollinger- Ellison syndrome |
| |
|
|
SIDE EFFECTS:
|
|
abdominal pain |
|
agitation |
|
agranulocytosis |
|
alopecia |
|
anaphylactoid reactions |
|
angioedema |
|
aplastic anemia |
|
arthralgia |
|
AV block |
|
blurred vision |
|
bronchospasm |
|
confusion |
|
constipation |
|
delirium |
|
depression |
|
diarrhea |
|
dizziness |
|
elevated hepatic enzymes |
|
eosinophilia |
|
erythema multiforme |
|
gynecomastia |
|
hallucinations |
|
headache |
|
hemolytic anemia |
|
hepatitis |
|
impotence |
|
insomnia |
|
jaundice |
|
leukopenia |
|
libido decrease |
|
maculopapular rash |
|
myalgia |
|
nausea/vomiting |
|
neutropenia |
|
pancreatitis |
|
pancytopenia |
|
paranoia |
|
premature ventricular contractions (PVCs) |
|
sinus bradycardia |
|
sinus tachycardia |
|
Stevens-Johnson syndrome |
|
thrombocytopenia |
|
toxic epidermal necrolysis |
|
vasculitis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
breast-feeding |
|
children |
|
elderly |
|
gastric cancer |
|
2-blocker*hypersensitivity#243"H2-blocker hypersensitivity |
|
infants |
|
infection |
|
neonatal prematurity |
|
neonates |
|
phenylketonuria |
|
porphyria |
|
pregnancy |
|
renal disease |
|
renal failure |
|
renal impairment |
|
|
ADULT DOSE:
|
|
Duodenal ulcer-Treatment: Oral, 150 mg two times a day or 300 mg at bedtime.
Prophylaxis of recurrent duodenal ulcer: Oral, 150 mg at bedtime.
Gastric ulcer, benign, active-Treatment: Oral, 150 mg two times a day.
Heartburn, acid indigestion, and sour stomach-Treatment: Oral, 75 mg at onset of symptoms; dose may be repeated once in twenty-four hours.
Prophylaxis: Oral, 75 mg thirty to sixty minutes before consuming food or beverages expected to cause symptoms.
Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas)-Oral, 150 mg two times a day, the dosage being adjusted as needed and therapy continued as long as clinically indicated. Doses up to 6 grams per day have been used in severe cases.
Gastroesophageal reflux-Oral, 150 mg two times a day.
Note: The recommended oral dose for erosive esophagitis is 150 mg four times a day.
Note: For patients with impaired renal function (creatinine clearance of less than 50 mL per minute)-Oral, 150 mg every twenty-four hours, the frequency of the dosage being increased to every twelve hours or more frequently, if necessary. Reductions in dosage may also be required if hepatic function impairment is present. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Duodenal ulcer or
Gastric ulcer-Oral, 2 to 4 mg per kg of body weight, two times a day up to a maximum dose of 300 mg per day.
Gastroesophageal reflux-Oral, 2 to 8 mg per kg of body weight per dose three times a day.
Note: In certain circumstances, doses may be titrated based on gastric pH. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Duodenal ulcer-Treatment: Oral, 150 mg two times a day or 300 mg at bedtime.
Prophylaxis of recurrent duodenal ulcer: Oral, 150 mg at bedtime.
Gastric ulcer, benign, active-Treatment: Oral, 150 mg two times a day.
Heartburn, acid indigestion, and sour stomach-Treatment: Oral, 75 mg at onset of symptoms; dose may be repeated once in twenty-four hours.
Prophylaxis: Oral, 75 mg thirty to sixty minutes before consuming food or beverages expected to cause symptoms.
Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas)-Oral, 150 mg two times a day, the dosage being adjusted as needed and therapy continued as long as clinically indicated. Doses up to 6 grams per day have been used in severe cases.
Gastroesophageal reflux-Oral, 150 mg two times a day.
Note: The recommended oral dose for erosive esophagitis is 150 mg four times a day.
Note: For patients with impaired renal function (creatinine clearance of less than 50 mL per minute)-Oral, 150 mg every twenty-four hours, the frequency of the dosage being increased to every twelve hours or more frequently, if necessary. Reductions in dosage may also be required if hepatic function impairment is present. |
|
|
|
|
|